search
Back to results

An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.

Primary Purpose

Pain

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
acetaminophen extended release caplets
Sponsored by
Johnson & Johnson Consumer and Personal Products Worldwide
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring muscle soreness, pain, acetaminophen, ibuprofen

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients must complete the marathon be able to swallow the study medication comply with study requirements regarding the use of any other pain medications before, during or after the marathon rate their muscle soreness on the evening after the marathon as at least a 4, on a zero-to-ten point scale if female, must not be pregnant or breastfeeding, and must be using an acceptable form of contraception Exclusion Criteria: Previous diagnosis of osteoarthritis requiring pain medication therapy currently have a major medical illness have a history of cardiovascular disease, heat injury (heat exhaustion or heat stroke) or collapse during a running or endurance event known hypersensitivity to acetaminophen or ibuprofen

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Average change in muscle soreness from baseline for both morning and evening assessments.

    Secondary Outcome Measures

    Average change in muscle soreness from baseline for morning assessments; Average change in muscle soreness from baseline for evening assessments; Average ratings of interference with 1) sleep; 2) morning activity; 3) ability to go for a run

    Full Information

    First Posted
    October 14, 2005
    Last Updated
    June 28, 2011
    Sponsor
    Johnson & Johnson Consumer and Personal Products Worldwide
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00240838
    Brief Title
    An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.
    Official Title
    A Randomized, Double-Blind Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2003 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    June 2003 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Johnson & Johnson Consumer and Personal Products Worldwide

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to compare the effectiveness and safety of acetaminophen extended release caplets and ibuprofen in relieving the muscle soreness that occurs after a marathon.
    Detailed Description
    The objective of this randomized, double-blind study is to compare the effectiveness and safety of acetaminophen extended release caplets and ibuprofen in relieving the muscle soreness that occurs in subjects who complete a marathon. Subjects are randomized to receive acetaminophen extended release caplets, 3900 mg/day (two 650 mg caplets taken three times a day, for five days) or ibuprofen caplets, 1200 mg/day (two 200 mg caplets taken three times a day, for five days). The primary measurement of efficacy is the average change in muscle soreness from baseline for both the morning and evening assessments. Safety assessments consist of monitoring adverse events, and a physical examination including vital signs, weight, a review of concomitant medications, and a urine pregnancy test for female subjects. Two hypotheses are examined in a step-down approach. The first hypothesis is that acetaminophen extended release is not inferior to ibuprofen in relieving the muscle soreness that occurs after a marathon. If acetaminophen extended release is not inferior to ibuprofen in relieving the muscle soreness that occurs after a marathon, the second hypothesis is that acetaminophen extended release (3900 mg/day) is superior to ibuprofen (1200 mg/day) in relieving the muscle soreness that occurs after a marathon. Two acetaminophen 650 mg extended release caplets, taken by mouth, three times a day for five days or two ibuprofen 200 mg caplets, taken by mouth, three times a day for five days.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pain
    Keywords
    muscle soreness, pain, acetaminophen, ibuprofen

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    483 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    acetaminophen extended release caplets
    Primary Outcome Measure Information:
    Title
    Average change in muscle soreness from baseline for both morning and evening assessments.
    Secondary Outcome Measure Information:
    Title
    Average change in muscle soreness from baseline for morning assessments; Average change in muscle soreness from baseline for evening assessments; Average ratings of interference with 1) sleep; 2) morning activity; 3) ability to go for a run

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients must complete the marathon be able to swallow the study medication comply with study requirements regarding the use of any other pain medications before, during or after the marathon rate their muscle soreness on the evening after the marathon as at least a 4, on a zero-to-ten point scale if female, must not be pregnant or breastfeeding, and must be using an acceptable form of contraception Exclusion Criteria: Previous diagnosis of osteoarthritis requiring pain medication therapy currently have a major medical illness have a history of cardiovascular disease, heat injury (heat exhaustion or heat stroke) or collapse during a running or endurance event known hypersensitivity to acetaminophen or ibuprofen
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial
    Organizational Affiliation
    McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Links:
    URL
    http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=912&filename=CR002866_CSR.pdf
    Description
    An Effectiveness and Safety Study comparing Acetaminophen (3900 mg/day) to Ibuprofen (1200 mg/day) in the Treatment of Post-Race Muscle Soreness.

    Learn more about this trial

    An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.

    We'll reach out to this number within 24 hrs